Epidemiology and clinical evolution of non-multisystem inflammatory syndrome (MIS-C) dermatological lesions in pediatric patients affected by SARS-CoV-2 infection: A systematic review of the literature
- PMID: 35948654
- PMCID: PMC9365226
- DOI: 10.1007/s00431-022-04585-7
Epidemiology and clinical evolution of non-multisystem inflammatory syndrome (MIS-C) dermatological lesions in pediatric patients affected by SARS-CoV-2 infection: A systematic review of the literature
Abstract
COVID-19 can present with a range of skin manifestations, some of which specific of the pediatric age. The aim of this systematic literature review was to determine the type, prevalence, time of onset, and evolution of cutaneous manifestations associated with COVID-19 in newborns, children, and adolescents, after excluding multisystem inflammatory syndrome in children (MIS-C). PubMed, Tripdatabase, ClinicalTrials, and Cochrane Library databases were searched using an ad hoc string for case reports/series and observational studies, published between December 2019 and February 2022. Study quality was assessed using the STROBE and CARE tools. Seventy-three (49 case reports/series and 24 studies) out of 26,545 identified articles were included in the analysis. Dermatological lesions were highly heterogeneous for clinical presentation, time of onset, and association with other COVID-19 manifestations. Overall, they mainly affected the acral portions, and typically presented a favorable outcome. Pseudo-chilblains were the most common.
Conclusions: Mucocutaneous manifestations could be the only/predominant and early manifestation of COVID-19 that could precede other more severe manifestations by days or weeks. Therefore, physicians of all disciplines should be familiar with them.
What is known: • A variety of cutaneous manifestations have been reported in association with COVID-19. • Urticaria, maculopapular, or vesicular rashes can occur at any age, while chilblains and erythema multiforme are more common in children and young patients.
What is new: • Skin lesions related to SARS-CoV-2 infection often show a peculiar acral distribution. • Mucocutaneous lesions of various type may be the only/predominant manifestation of COVID-19; they could present in paucisymptomatic and severely ill patients and occur at different stages of the disease.
Keywords: COVID-19; Cutaneous acral lesions; Erythema multiforme; Pediatric dermatology; Pseudo-chilblains.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
The authors declare no competing interests.
Figures
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Measures implemented in the school setting to contain the COVID-19 pandemic.Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 May 2;5:CD015029. doi: 10.1002/14651858.CD015029.pub2. PMID: 35037252 Free PMC article. Updated.
Cited by
-
MIS-C across three SARS-CoV-2 variants: Changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children.Eur J Pediatr. 2023 Jun;182(6):2865-2872. doi: 10.1007/s00431-023-04968-4. Epub 2023 Apr 13. Eur J Pediatr. 2023. PMID: 37055630 Free PMC article.
-
Editorial: COVID-19 and hyper inflammation syndrome: Different presentation and management.Front Pediatr. 2022 Sep 9;10:1022701. doi: 10.3389/fped.2022.1022701. eCollection 2022. Front Pediatr. 2022. PMID: 36160806 Free PMC article. No abstract available.
-
COVID-19 and Related Vaccinations in Children: Pathogenic Aspects of Oral Lesions.Children (Basel). 2023 Apr 29;10(5):809. doi: 10.3390/children10050809. Children (Basel). 2023. PMID: 37238357 Free PMC article. Review.
References
-
- Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP et al (2021) Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: A retrospective surveillance study. Lancet Child Adolesc Heal [Internet] 5(5):323–31. Available from: 10.1016/S2352-4642(21)00050-X - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous